Sun Pharma Advanced Research Company's Q1 FY 2025-26 Quarterly Results

Result Summary

• Sun Pharma Advanced Research Company Ltd reported a 10.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.2%.
• Its expenses for the quarter were down by 44.1% QoQ and 38.0% YoY.
• The net profit decreased 51.0% QoQ and decreased 45.9% YoY.
• The earnings per share (EPS) of Sun Pharma Advanced Research Company Ltd declined at 1.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharma Advanced Research Company Ltd (SPARC) is a biopharmaceutical company engaged in the research and development of pharmaceutical products. The company primarily focuses on the development of new chemical entities and novel drug delivery systems. SPARC operates in the healthcare industry, which is characterized by rapid innovation and significant investment in research and development. As of the latest data, no specific recent major developments are available for SPARC.

Revenue

For the first quarter of fiscal year 2026 (Q1FY26), Sun Pharma Advanced Research Company Ltd reported a total income of ₹18.78 crores. This represents a decrease of 10.4% compared to the previous quarter (Q4FY25), where the total income stood at ₹20.96 crores. However, there was a slight increase of 2.2% when compared to the same quarter in the previous fiscal year (Q1FY25), which recorded a total income of ₹18.37 crores. These figures highlight the changes in the company's revenue generation capabilities over the recent quarters and year-on-year.

Profitability

The financial data for Q1FY26 indicates a Profit Before Tax (PBT) of -₹51.81 crores, showing a significant improvement of 50.8% from the previous quarter's PBT of -₹105.41 crores. Compared to the same quarter of the previous year, there is also a 45.7% improvement from a PBT of -₹95.50 crores. The company's Profit After Tax (PAT) for Q1FY26 was -₹51.87 crores, which is a 51.0% improvement over Q4FY25 and a 45.9% improvement over Q1FY25. Earnings Per Share (EPS) for the current quarter is reported at -₹1.60, reflecting a 51.5% improvement quarter-over-quarter and a 46.7% improvement year-over-year. Despite negative profitability figures, the company has shown significant improvement in its financial performance compared to previous periods.

Operating Metrics

Sun Pharma Advanced Research Company Ltd's total expenses for Q1FY26 were ₹70.59 crores, which is a notable decrease of 44.1% from Q4FY25's expenses of ₹126.37 crores. Compared to Q1FY25, expenses decreased by 38.0% from ₹113.87 crores. These figures indicate a significant reduction in the company's operating costs. The tax expense for the current quarter was ₹0.06 crores, showing a substantial reduction of 84.2% from the previous quarter and 85.0% from the same quarter last year. These metrics provide insight into the company's cost management and operational efficiency over the reviewed periods.